SuperworthLiquidia market cap LQDA
Share price times shares outstanding: what the whole company sells for, since 2018.
- Today, Oct 23, 2026
- $3.8B
- Highest close in our data
- $8B
- Aug 2026
Liquidia is worth $3.8B at the close on Oct 23, 2026, at $42.65 a share.
That is up 98% over the last year and up 1859% over five years.
Its highest close in our data was $8B in Aug 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $3.8B | $2.5B | $8B | +28% |
| 2025 | $3B | $1B | $3B | +206% |
| 2024 | $979.2M | $698.8M | $1.3B | +25% |
| 2023 | $780.8M | $368.9M | $780.8M | +90% |
| 2022 | $410.8M | $250.3M | $483.4M | +62% |
| 2021 | $253.1M | $98.5M | $259.4M | +127% |
| 2020 | $111.4M | $74.6M | $309.3M | +21% |
| 2019 | $92.2M | $57.8M | $311.4M | −73% |
| 2018 | $344.5M | $229.9M | $481.6M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Liquidia's size, closest first, today.
| Company | Market cap |
|---|---|
| LQDALiquidia | $3.8B |
| ARQTArcutis Biotherapeutics | $3.9B |
| OGNOrganon | $3.6B |
| INDVIndivior Pharmaceuticals | $4.1B |
| NRIXNurix Therapeutics | $2.8B |
| KNSAKiniksa Pharmaceuticals International | $6B |
| LGNDLigand Pharmaceuticals | $6.1B |
| PBHPrestige Consumer Healthcare | $2.3B |
| AMRXAmneal Pharmaceuticals | $6.5B |
| HRMYHarmony Biosciences | $2.1B |
| ALKSAlkermes plc. | $7.3B |
| Peer median | $4B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Liquidia
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.